SCHEDULE: Kynam Capital Discloses 5.27% Stake in Cullinan Therapeutics

Kynam Capital Management, LP, along with its general partner and managing member, has reported a beneficial ownership of 5.27% in Cullinan Therapeutics, Inc. as of December 31, 2025.

Summary

• Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang collectively beneficially own 3,114,132 shares of Cullinan Therapeutics, Inc. Common Stock.
• This ownership represents 5.27% of the total class of securities.
• The shares are held with shared voting power and shared dispositive power among the reporting persons.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates an institutional investor has taken a significant stake in Cullinan Therapeutics, suggesting confidence in the company's long-term prospects without implying any intent to influence control.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional investor filings like this Schedule 13G provide transparency into significant ownership stakes, which can sometimes signal investor confidence or strategic positioning within the biotechnology sector. While this filing does not provide operational details, a new or increased stake by an investment firm in a biotech company like Cullinan Therapeutics can be viewed by the market as a positive indicator of potential future value, especially given the capital-intensive nature of drug development.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence trading activity.

Key Dates

Keywords

Cullinan Therapeutics, Kynam Capital Management, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investor, Biotechnology, Healthcare